Skip to main content

Table 1 Clinical status of RAp and HD

From: Interleukin-17A- or tumor necrosis factor α-mediated increase in proliferation of T cells cocultured with synovium-derived mesenchymal stem cells in rheumatoid arthritis

 

RAp

HD

Number of Patients

22

8

Sex

  

  Men

11 (50%)

4 (50%)

  Woman

11 (50%)

4 (50%)

Age (years)

42 (38 to 56)

40 (35 to 46)

Disease duration (years)

3.1 (0.2 to 5.5)

2.6 (0.1 to 4.6)

Treatment, patients (%)

  

  None

15 (68%)

7 (87.5%)

  MTX

2 (9%)

-

  MTX + SSZ

2 (9%)

-

  NSAIDs

-

1 (12.5%)

  Otherb

3 (14%)

-

VAS

14 (5 to 35)

1 (0 to 2)

  1. bOther treatments may have included corticosteroids, azathioprine, or leflunomide. In the HD group, disease duration refers to the duration of meniscus injury.
  2. HD, healthy donor; MTX, methotrexate; Rap, patients with rheumatoid arthritis (RA); SSZ, sulfasalazine; NSAIDs, nonsteroidal antiinflammatory drugs; VAS, visual analogue score.